Cite
Ding PN, Roberts TL, Chua W, et al. Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. Transl Lung Cancer Res. 2021;10(4):1623-1634doi: 10.21037/tlcr-20-1125.
Ding, P. N., Roberts, T. L., Chua, W., Becker, T. M., Caixeiro, N., de Souza, P., Gao, B., Lee, C. K., Itchins, M., Westman, H., Clarke, S., Blinman, P., Kao, S., John, T., Leal, J. L., & Bray, V. J. (2021). Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. Translational lung cancer research, 10(4), 1623-1634. https://doi.org/10.21037/tlcr-20-1125
Ding, Pei N, et al. "Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib." Translational lung cancer research vol. 10,4 (2021): 1623-1634. doi: https://doi.org/10.21037/tlcr-20-1125
Ding PN, Roberts TL, Chua W, Becker TM, Caixeiro N, de Souza P, Gao B, Lee CK, Itchins M, Westman H, Clarke S, Blinman P, Kao S, John T, Leal JL, Bray VJ. Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. Transl Lung Cancer Res. 2021 Apr;10(4):1623-1634. doi: 10.21037/tlcr-20-1125. PMID: 34012779; PMCID: PMC8107763.
Copy
Download .nbib